Protection of the prostate in conditions of chronic pelvis varicose


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Introduction. Chronic prostatitis is the most common urological disease. The morphological outcome of chronic inflammation is sclerosis, leading to the loss of functional active tissue. Venous congestion of the small pelvis can act as a trigger factor in the development of prostate sclerosis. Venotonics in combination with antioxidants may be considered for organoprotection of the prostate in pelvic varicose veins. Purpose: to evaluate the protective effect of an antioxidant, venotonic and their combination on the process of formation of connective tissue in the prostate gland against the background of pelvic varicose veins in a chronic experiment. Materials and methods. The experiment was carried out on a proven model of chronic venous congestion of the small pelvis and was carried out on 64 sexually mature rabbits weighing 2.6-3.2 kg. 5 groups have been identified. In the first group (n=15), an assessment of the effect of isolated antioxidant (resveratrol) was carried out. In the second group (n=15), an assessment of the effect of isolated venotonic (diosmin) was studied. In the third group (n=15), the effect of a combination of an antioxidant (resveratrol) and venotonic (diosmin) was evaluated. An aqueous solution of the preparations was injected daily for 180 days. In the fourth group (n=15), changes in the prostate were assessed against the background of venous congestion without exposure. In the fifth group (n= 4), animals performed to provide data on normal anatomy. The animals were taken out of the experiment at 30, 90, 180 days. Prostate tissue was collected for histological examination and morphometry. In prostate samples, the concentration of hydroxyproline, a marker of connective tissue development, was investigated. Results: the isolated administration of resveratrol, as well as diosmin, does not sufficiently compensate for the changes in the hemodynamics of the small pelvis and the toxic effect of metabolic products. With morphometry on day 180, the proportion of glandular tissue in the gland / fibrosis ratio was significantly higher, and fibrosis was lower in Group 3 (79.36 / 9.08 (p<0.01) than in Group 1 (63.1 / 22.74) and Group 2 (65.52 / 21.0) .Quantitative study of hydroxyproline showed lower concentrations in the samples of Group 3 18.44 mg% (p<0.01), relative to Groups 1 and 2 (39.7 and 34.44 mg%) There were no statistically significant differences in the studied parameters between Groups 1 and 2. Conclusion: the use of a combination of diosmin and resveratrol against the background of chronic venous hyperemia allowed, in the course of the presented experiment, to reduce the lesion volume and the growth of fibrous tissue in the prostate gland. The approach itself requires further study.

Full Text

Restricted Access

About the authors

A. Y Tsukanov

Omsk State Medical University

Email: autt@mail.ru
professor of medicine, chief of the Department of Surgery and Urology Omsk, Russia

N. V Rudchenko

Omsk State Medical University

Email: simozgovoy@yandex.ru
postgraduate of the Department of Surgery and Urology Omsk, Russia

S. I Mozgovoy

Omsk State Medical University

Email: nrudrus@gmail.com
DrSc, , professor of medicine, Associate Professor of the Department of Pathological Anatomy Omsk, Russia

A. V Maslyukov

Omsk State Medical University

Email: maslyukov.a@inbox.ru
student Omsk, Russia

References

  1. Белоусов И.И., Черногубова Е.А., Коган М.И. Роль эндотелиальной дисфункции в патогенезе невоспалительной формы хронического абактериального простатита. Урология. 2013;3:39-42
  2. Коган М.И., Белоусов И.И., Болоцков А.С. Артериальный кровоток в простате при синдроме хронической тазовой боли/ хроническом простатите. Урология. 2011;3:22-28
  3. Состояние леваторных мышц как один из факторов в развитии синдрома тазовой боли у мужчин. Бюллетень сибирской медицины. 2012; 11(2):31-35.) https://doi.org/10.20538/1682-0363-2012-2-31-35
  4. Клименко П.М., Чабанов В.А., Шимкус С.Э. Нарушение интраорганного кровоснабжения - причина болевого синдрома при простатите и его гемодинамическая коррекция. Крымский журнал экспериментальной и клинической медицины. 2015; 3(19):28-34
  5. Абудуев Н.К., Кубанова А.А., Васильев М.М. и др. Опыт применения детралекса в комплексном лечении больных хроническим уретрогенным простатитом. Вестник дерматологии. 2001;5:65-67
  6. Zeitli«SI. Is prostatitis a vascular disease? J Urol. 2011;186(3):781-782
  7. Azadzoi K.M., Tarca«T., Siroky M.B., Kra«e R.J. Atherosclerosis-induced chronic ischemia causes bladder fibrosis and non-compliance in the rabbit. J. Urol. 1999;161:1626-1635
  8. Kapoor H., Gupta E., Sood A. Chronic pelvic ischemia: etiology, pathogenesis, clinical presentation and management. Minerva Urol Nefrol. 2014;66(2):127-137
  9. O«o T, Berga«JJ, Schmid-Scho«bei«GW, et al. Monocyte infiltration into venous valves. Journal of vascular surgery. 1998;27(1):158-66
  10. Цуканов А.Ю., Рудченко Н.В., Ахметов Д.С., Алябушев С.Ф. Модель варикоза малого таза в хроническом эксперименте. Экспериментальная и клиническая урология. 2019;1:28-31) doi: 10.29188/2222-8543-201911-1-28-31
  11. Новиков В.Е., Левченкова О.С. Новые направления поиска лекарственных средств с антигипоксической активностью и мишени для их действия. Экспериментальная и клиническая фармакология 2013; (76)5:37-47
  12. Новиков В.Е., Понамарёва Н.С., Шабанов П.Д. Аминотиоловые антигипоксанты при травматическом отеке мозга. СПб.: Элби-СПб. 2008;176 с
  13. Чеснокова Н.П., Понукалина Е.В., Бизенкова М.Н. Молекулярно-клеточные механизмы инактивации свободных радикалов в биологических системах. Успехи современного естествознания. 2006;7:29-36
  14. Шилов А.М. Антигипоксанты и антиоксиданты (актовегин) в программе лечения ишемической болезни сердца. Архивъ внутренней медицины. 2013;4(12):41-50
  15. Carter L.G., D’Orazio J.A., Pearso« K.J. Resveratrol and cancer: focus on in vivo evidence Endocr. Relat. Cancer. 2014; 21(3):209-225.
  16. Delmas D., La«co« A., Coli« D. et al. Resveratrol as a chemopreventive agent: a promising molecule for fighting cancer. Curr. Drug Targets 2006; 7: 423-442.
  17. Jaug M. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science;1997;275(5297):218-220.
  18. Karuppagou«der S. Dietary supplementation with resveratrol reduces plaque pathology in a transgenic model of Alzheimer’s disease. Neurochem. Int.;2009;54(2):111-118.
  19. Wu, J. M. Wang Tzeche-Hsiesh, Z. Cardioprotection by resveratrol: a review of effects/targets in cultured cells and animal tissues. Am J Cardiovasc Dis.;2011;1(1):38-47.
  20. Просянников М.Ю., Константинова О.В., Голованов С.А., Анохин Н.В., Войтко Д.А. Результаты применения препарата растительного происхождения с антиоксидантной защитой при мочекаменной болезни. Урология; 2020;4:55-59.) https://dx.doi.org/10.18565/urology.2020.4.55-59
  21. Vicari E., Ara«cio A., Catania V.E. Resveratrol reduces inflammation-related Prostate Fibrosis. Int J Med Sci. 2020;17(13):1864-1870. Doi:10.7150/ ijms.44443.
  22. Den Hartogh D.J., Tsiani E. Health Benefits of Resveratrol in Kidney Disease: Evidence from In Vitro and In Vivo Studies. Nutrients. 2019;11(7):1624. doi: 10.3390/nu11071624.
  23. Corsale I, Carrieri P, Martellucci J, et al. Flavonoid mixture (diosmin, troxerutin, rutin, hesperidin, quercetin) in the treatment of I-III degree hemorroidal disease: a double-blind multicenter prospective comparative study. Int J Colorectal Dis. 2018;33(11):1595-1600. doi: 10.1007/s00384- 018-3102-y.
  24. Sliva J. Diosmin - still an important modality in the treatment of venous insufficiency. Vnitr Lek. 2019;65(7-8):524-526.
  25. Шекунова Е.В., Ковалева М.А., Макарова М.Н., Макаров В.Г. Выбор дозы препарата для доклинического исследования: межвидовой перенос доз. Ведомости Научного центра экспертизы средств медицинского применения. 2020;10(1):19-28
  26. Carrizzo A, Vecchione C, Damato A, et al. Rac1 Pharmacological Inhibition Rescues Human Endothelial Dysfunction. Journal of the American Heart Association. 2017;6(3).
  27. Colombo P.C., Onat D., Harxhi A., et al. Peripheral venous congestion causes inflammation, neurohormonal, and endothelial cell activation. European heart journal. 2014;35(7):448-454.
  28. Камалов А.А., Охоботов Д.А., Проскурнина Е.В., Созарукова М.М., Низов А.Н. Антиоксидантная активность и клиническая эффективность биологически активной добавки Нефрадоз в лечении рецидивирующего кальций-оксалатного уролитиаза. Урология. 2018;6:52-59

Supplementary files

Supplementary Files
Action
1. JATS XML

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies